This observational study aims to investigate the impact of GGCX gene mutations and GGCX levels on stroke prognosis in patients with ischemic stroke, as well as their correlation. The main issues are:
What is the relationship and potential mechanism between GGCX gene mutations and their expression levels and the composite prognosis of recurrence, death, and bleeding events in patients with ischemic stroke? Collect blood samples from enrolled ischemic stroke patients for genetic testing, and conduct follow-up visits at 3, 6, and 12 months after discharge to evaluate clinical prognosis outcomes. This will answer questions about the relationship and mechanism between GGCX gene and patient prognosis.
Aged between 18 and 85 years.
Diagnosed with ischemic stroke (in accordance with the "Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke 2023," including TOAST etiological/pathogenic subtypes: large-artery atherosclerosis (LAA), cardioembolism (CE), small-artery occlusion (SAO), stroke of other determined etiology (SOE), and stroke of undetermined etiology (SUE)).
Acute onset, with symptoms occurring within 72 hours and being the first episode.
Voluntary participation with signed informed consent.
Patients with cerebrovascular diseases occurring within 72 hours.
Pregnant or lactating patients.
Other types of stroke, including hemorrhagic stroke, mixed stroke, and tumor-related stroke patients.
Patients with coagulation disorders or other hematologic diseases.
Peking University Aerospace Center Hospital
Lead sponsor
Aerospace Center Hospital
Sponsor institution